Evolus, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EOLS research report →
Companywww.evolus.com
Evolus, Inc. , a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
- CEO
- David Moatazedi
- IPO
- 2018
- Employees
- 372
- HQ
- Newport Beach, CA, US
Price Chart
Valuation
- Market Cap
- $433.98M
- P/E
- -9.89
- P/S
- 1.44
- P/B
- -14.93
- EV/EBITDA
- -39.13
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 65.55%
- Op Margin
- -9.56%
- Net Margin
- -14.39%
- ROE
- 174.92%
- ROIC
- -18.60%
Growth & Income
- Revenue
- $297.18M · 11.61%
- Net Income
- $-51,641,000 · -2.42%
- EPS
- $-0.80 · 1.23%
- Op Income
- $-37,600,000
- FCF YoY
- -134.74%
Performance & Tape
- 52W High
- $10.62
- 52W Low
- $3.86
- 50D MA
- $5.10
- 200D MA
- $5.97
- Beta
- 1.29
- Avg Volume
- 1.13M
Get TickerSpark's AI analysis on EOLS
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 20, 26 | Avelar Rui | sell | 3,119 |
| Mar 20, 26 | MOATAZEDI DAVID | sell | 13,669 |
| Mar 16, 26 | MOATAZEDI DAVID | other | 67,489 |
| Mar 17, 26 | MOATAZEDI DAVID | sell | 116,720 |
| Mar 16, 26 | MOATAZEDI DAVID | other | 67,489 |
| Mar 16, 26 | Avelar Rui | other | 8,804 |
| Mar 17, 26 | Avelar Rui | sell | 29,996 |
| Mar 16, 26 | Avelar Rui | other | 8,804 |
| Feb 17, 26 | Parschauer Karah Herdman | other | 45,559 |
| Feb 17, 26 | Stewart Brady | other | 45,559 |
Our EOLS Coverage
We haven't published any research on EOLS yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate EOLS Report →